Last reviewed · How we verify
Doxycycline post-exposure prophylaxis
Doxycycline post-exposure prophylaxis is a Tetracycline antibiotic Small molecule drug developed by University of Washington. It is currently FDA-approved for Post-exposure prophylaxis for anthrax (Bacillus anthracis), Post-exposure prophylaxis for other susceptible bacterial pathogens. Also known as: doxyPEP.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing pathogenic bacteria from multiplying after potential exposure.
Doxycycline is used as post-exposure prophylaxis, as indicated by ClinicalTrials.gov in the "Doxy-PEP: Dose-Ranging Study of Persons Receiving Doxycycline" study. As a small molecule, doxycycline works through its mechanism of action, which is not specified in the provided facts, but is documented in ChEMBL.
At a glance
| Generic name | Doxycycline post-exposure prophylaxis |
|---|---|
| Also known as | doxyPEP |
| Sponsor | University of Washington |
| Drug class | Tetracycline antibiotic |
| Target | Bacterial 30S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Doxycycline is a tetracycline antibiotic that works by inhibiting bacterial protein synthesis, making it effective as post-exposure prophylaxis against susceptible organisms. When used prophylactically after potential exposure to pathogens such as Bacillus anthracis (anthrax) or other bacteria, it prevents infection establishment by suppressing bacterial growth before clinical disease develops. The drug is bacteriostatic, meaning it stops bacterial replication rather than directly killing the organisms.
Approved indications
- Post-exposure prophylaxis for anthrax (Bacillus anthracis)
- Post-exposure prophylaxis for other susceptible bacterial pathogens
Common side effects
- Photosensitivity
- Nausea and vomiting
- Esophageal irritation
- Diarrhea
- Vaginal yeast infection
- Headache
Key clinical trials
- The Efficacy of Doxycycline Post Exposure Prophylaxis for Preventing STIs Among MSM in Bangkok, Thailand. (PHASE4)
- Sexual Health Access at Retail Pharmacies: Advancing Pharmacy-based Delivery of Primary STI and HIV Prevention for Cisgender Women (NA)
- Got Doxy- 'Flipping the Script' on STI PEP (PHASE4)
- Periodic Presumptive Treatment vs. doxyPEP for STI Control in Kenyan MSM (PHASE4)
- Doxy-Post-exposure Prophylaxis (PHASE4)
- Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study (PHASE2)
- Parrying the Pitfalls of PrEP: Project PEACH (PHASE4)
- Superiority of On-demand PrEP Versus PEP on Using Doxycycline for Preventing STI in MSM (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Doxycycline post-exposure prophylaxis CI brief — competitive landscape report
- Doxycycline post-exposure prophylaxis updates RSS · CI watch RSS
- University of Washington portfolio CI
Frequently asked questions about Doxycycline post-exposure prophylaxis
What is Doxycycline post-exposure prophylaxis?
How does Doxycycline post-exposure prophylaxis work?
What is Doxycycline post-exposure prophylaxis used for?
Who makes Doxycycline post-exposure prophylaxis?
Is Doxycycline post-exposure prophylaxis also known as anything else?
What drug class is Doxycycline post-exposure prophylaxis in?
What development phase is Doxycycline post-exposure prophylaxis in?
What are the side effects of Doxycycline post-exposure prophylaxis?
What does Doxycycline post-exposure prophylaxis target?
Related
- Drug class: All Tetracycline antibiotic drugs
- Target: All drugs targeting Bacterial 30S ribosomal subunit
- Manufacturer: University of Washington — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Post-exposure prophylaxis for anthrax (Bacillus anthracis)
- Indication: Drugs for Post-exposure prophylaxis for other susceptible bacterial pathogens
- Also known as: doxyPEP
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing